Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$80,000
What the client paid this registrant for the period.
Lobbyists on this filing
3
-
ROBERT BUTORAPreviously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
-
JEANNE HAGGERTY New on this filingPreviously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
-
CHRISTOPHER E. WILCOXPreviously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
Government bodies contacted
2
Lobbying activity
5
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Issues related to TrumpRX.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. Issues related to China WRT the BINSA bill.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
Issues related to China WRT the BINSA bill.